Similar to phenformin, an oral biguanide antidiabetic medicine that was taken off the market in the US in 1977 due to the onset of lactic acidosis, metformin is a biguanide antidiabetic agent. But with metformin, the chance for this adverse effect is significantly reduced. 1 While metformin’s effects are distinct from those of sulfonylureas and other anti-diabetic medications, they nonetheless work well together. In type 2 diabetes, metformin was discovered to produce comparable glycemic control to glyburide. even if it increased the likelihood of stomach issues. 2 In the treatment of polycystic ovarian syndrome (PCOS), metformin has been demonstrated to be effective; it reduces blood androgen levels, restores regular menstrual periods and ovulation, and may increase the likelihood of conception. 3 Additionally, based on the little data available, it may postpone the development of menarche in females who have precocious puberty and the onset of puberty in females who have an early-normal onset. 45 Both metformin and rigorous lifestyle change are effective in reducing the occurrence of diabetes, but lifestyle intervention has a stronger impact in patients with impaired glucose tolerance. 6 Even while lifestyle intervention is quite successful, the majority of patients who try lifestyle changes on their own during the first year after diagnosis fail. Therefore, it is advised that metformin and lifestyle interventions be started as soon as type 2 diabetes mellitus is diagnosed, according to a joint consensus algorithm for the treatment of the condition created by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes. The effectiveness, safety, and affordability of metformin led to its selection as the first pharmacological therapy. 789 In addition, in a follow-up study to the UKPDS, researchers discovered that patients initially randomized to metformin therapy had a 33 percent relative reduction in risk of myocardial infarction and a 27 percent relative reduction in risk of death from any cause as compared to patients initially randomized to conventional therapy after 10 years of resuming typical care (RR 0.67, 95 percent CI 0.51—0.89; p=0.005). 10 The FDA did not approve metformin until December 1994, despite the fact that it had been available in Europe since the 1950s. It can be used alone or in conjunction with sulfonylureas, alpha-glucosidase inhibitors, or insulin to treat type 2 diabetes. In January 2001, the regular-release pills received approval for usage in children older than 10 years. In September 2003, Riomet, an oral treatment, received approval. Glucophage XR in October 2000, Fortamet in April 2004, and Glumetza in June 2005, each with a different medication delivery method, are three extended-release formulations that have been approved (see Pharmacokinetics section). When compared to regular-release metformin, the extended-release versions offer comparable glucose control, but have the benefit of once-daily treatment. Another benefit is the promise of less side effects, particularly gastrointestinal side effects (such as flatulence and diarrhea); however, larger trials contrasting regular-release and extended-release metformin are required to support these claims as the present trial results are inconsistent. 111213